The Opioid Crisis: How a Pharma Marketing Campaign Became a Public Health Disaster

In January 1980 the New England Journal of Medicine printed a paragraph. Not an article — a paragraph, five sentences long, tucked into the correspondence pages under the heading “Addiction Rare in Patients Treated with Narcotics”. Two authors, Hershel Jick and Jane Porter, reported that of nearly twelve thousand hospital patients given opioids, only four had developed an addiction with no prior history. That was the whole thing. It described patients in hospital beds, monitored, on short courses. Sixteen years later a pharmaceutical company would lift that paragraph out of context, wave it at doctors across America, and use it to help sell a drug that killed more people than the Vietnam War. This is the story of a marketing campaign that became a mass-casualty event, and of how a mostly true account of corporate wrongdoing acquired a few load-bearing errors on its way to becoming common knowledge.

The five-sentence letter

The Porter and Jick letter is worth pausing on, because so much rests on it. It was a genuine finding, honestly reported, about a specific and narrow population: people receiving opioids in a controlled hospital setting, mostly for acute pain, mostly briefly. It said nothing about patients sent home with a bottle of pills for months of back pain. It was a snapshot of monitored inpatient care, and it described that and only that.

Over the following decades it was cited hundreds of times, and a striking number of those citations misdescribed it — calling it an “extensive study”, claiming it proved that opioids prescribed for chronic pain almost never caused addiction. A 2017 analysis in the same journal traced this citation history and found the letter had been “heavily and uncritically cited as evidence that addiction was rare”. A single paragraph, detached from its context, hardened into a licence. It was the kind of citation that people repeat because it is convenient and because someone respectable said it first.

The pharmaceutical industry did not invent the idea that pain was being undertreated. Through the 1980s and 1990s a real and well-intentioned movement argued that doctors, frightened of opioids, were leaving cancer patients and the dying in needless agony. That movement had a point. What happened next was that a commercial interest attached itself to a compassionate cause and rode it into territory the evidence never covered.

Purdue and the launch of OxyContin

The company was Purdue Pharma, privately owned by the Sackler family. In 1996 it launched OxyContin, a controlled-release formulation of oxycodone. The pitch was clever. Because the drug released its dose slowly over twelve hours, Purdue argued, it produced steadier blood levels and therefore — the reasoning went — a lower risk of the euphoric spikes that drive abuse and addiction. The label, approved by the US Food and Drug Administration in 1995, went further than that reasoning could bear, stating that delayed absorption “is believed to reduce the abuse liability of a drug”. That single sentence, which no clinical trial had established, became the spine of the marketing.

Purdue built a sales operation of unusual intensity. It compiled prescriber databases to find the highest-volume opioid prescribers in the country and sent representatives to them. It funded pain-management “education”, underwrote professional bodies, distributed branded merchandise — the fishing hats and plush toys that would later look grotesque — and ran a bonus scheme that paid representatives lavishly for driving up prescriptions. It promoted the claim, repeated to doctors again and again, that the risk of addiction in pain patients was “less than one per cent”. The source for that figure traced back, through a chain of citations, to exactly the kind of context-free reading of small studies and letters that the Porter and Jick paragraph exemplified.

The twelve-hour claim mattered commercially, and it was shaky in practice. For a substantial number of patients the drug wore off well before twelve hours, producing a trough of pain and early withdrawal between doses. The clinically obvious fix would have been more frequent dosing. But twelve-hour dosing was OxyContin’s competitive advantage, so the company’s guidance pushed doctors instead towards higher individual doses — larger pills, further apart. Higher doses meant more drug in the patient, more physical dependence, and more product on the street.

What is documented, and how it broke

Here is the kernel, and it is not in serious dispute, because a federal court established it. In 2007 Purdue Frederick, an affiliate of Purdue Pharma, and three of its top executives pleaded guilty in the Western District of Virginia to criminal charges relating to the misbranding of OxyContin. The company admitted that it had marketed the drug with the intent to mislead about its risk of addiction and abuse. Internal materials showed that the company had known its “less abuse potential” messaging outran the evidence. The settlement came to around 600 million dollars — a large figure for the time, and, against the revenues OxyContin generated, a rounding error. No executive went to prison; the individuals pleaded to misdemeanours.

That plea is the bedrock fact. A drug company was convicted of lying about how addictive its opioid was, during the years it was seeding a national dependence. Everything the public came to believe about Purdue’s dishonesty was, in its essentials, correct and proven in court.

The mechanism of exposure is worth understanding, because it shows how slowly these things surface. The early alarm did not come from regulators. It came from the ground — from doctors in rural Maine, Appalachia and the Rust Belt who began seeing crushed and snorted tablets, from pharmacists watching prescription volumes, from small-town newspapers in coalfield counties that ran the obituaries and did the arithmetic, and from a Virginia federal prosecutor named John Brownlee who pursued the case against the company’s wishes and against pressure from within his own government. The tablets themselves made the abuse easy: because the entire twelve-hour dose sat in a single pill, crushing one and snorting or injecting it delivered a hit that the slow-release coating had been meant to prevent — a design that turned the drug’s selling point into its street value. The drug had been on the market for over a decade, and hundreds of thousands were already dependent, by the time the first criminal reckoning arrived. The tobacco industry’s own internal documents had taught a generation of lawyers how to read a company’s private knowledge against its public claims, and that template was now turned on pharma.

Where the story bends

Now the fork — the part where popular belief adds something the record does not quite support, and where the honest version is more useful than the tidy one.

The tidiest telling goes: Purdue created the opioid crisis; OxyContin is the crisis; the Sacklers killed half a million people. Each clause contains truth and each overstates it.

The crisis has been described by epidemiologists as arriving in three waves. The first, beginning in the late 1990s, was driven by prescription opioids — OxyContin prominent among them, but not alone; other manufacturers, distributors and pharmacy chains were all part of an oversupplied system, and later litigation reached far beyond Purdue. The second wave, from around 2010, was heroin, as many people who had become dependent on pills — some after Purdue reformulated OxyContin in 2010 to be harder to crush — moved to a cheaper street drug. The third and deadliest wave, from around 2013, was illicitly manufactured fentanyl and its analogues, which now account for the large majority of overdose deaths. The commonly cited figure of more than half a million American opioid deaths since 1999 is real, but the great bulk of recent deaths involve fentanyl that Purdue never made and never sold.

To say this is not to acquit the company. The most persuasive account is that Purdue’s marketing did something specific and grievous: it helped normalise long-term opioid prescribing for ordinary chronic pain, expanding the pool of dependent people and the cultural permission around these drugs, and that pool became the tinder for everything that followed. The reformulation that pushed users towards heroin was itself a consequence of the dependence the company had helped manufacture. Causation here runs as a chain, each link pulling the next. The mythologised version collapses the chain into one villain because one villain is easier to hold in the mind — and because a family with a name on museum walls made an irresistible target.

Why the simple version wins

There is a reason the compressed story travels better than the accurate one, and it is not stupidity. It is that the accurate story is unbearable in a different way. A single evil company is a problem with a solution: sue it, jail its owners, feel that justice has closed the account. A crisis produced by a whole system — compliant regulators who approved that label, medical bodies that declared pain the “fifth vital sign” and pushed hospitals to treat it more aggressively, distributors shipping millions of pills into towns of a few thousand people, a culture that wanted a pill for everything and a healthcare system too rushed to offer anything slower — that is a problem with no defendant and no verdict that closes it.

The families who lost someone did not misremember out of carelessness. They reached for the version with a face on it because grief needs somewhere to go, and “the system failed in a hundred diffuse ways” gives grief nowhere to stand. When people insist that OxyContin is the opioid crisis, they are not making an epidemiological error so much as an moral demand: that someone be held to account, that the deaths mean something, that the account not be closed with a 600-million-dollar fine and three misdemeanours while the money stayed in the family.

The same instinct animates the way the Sacklers’ philanthropy was later re-read — every gallery wing suddenly a laundering of the same money, every donated coin traced back to a pill bottle. Some of that re-reading was fair and some ran ahead of the evidence, in exactly the pattern this case keeps repeating: a true and damning core, wrapped in an outer layer of retribution that claims more than the documents hold. It echoes an older pharmaceutical reckoning, the thalidomide disaster, where a genuine cover-up hardened in memory into a simpler morality tale than the record could sustain.

The crisis is not a mystery that needs a conspiracy to explain it. The paper trail is public; the guilty plea is on file; the misbranding was admitted. What the episode leaves behind is harder to file away than a verdict — the knowledge that a five-sentence letter, honestly written, could be turned into a weapon; that a compassionate movement to treat pain could be captured by the people selling the pills; and that when the account finally came due, the mechanism built to deliver justice returned a fine, three misdemeanours, and a family still rich enough to have its name carved above the doors of the world’s great museums. Understanding that is less satisfying than a gavel. It is also the only thing that helps.